---
title: "Lvpai Group reports Q3 net loss of USD 7,100"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274878827.md"
datetime: "2026-02-04T22:23:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274878827.md)
  - [en](https://longbridge.com/en/news/274878827.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274878827.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274878827.md) | [English](https://longbridge.com/en/news/274878827.md)


# Lvpai Group reports Q3 net loss of USD 7,100

Lvpai Group Ltd. reported its financial results for the third quarter ended October 31, 2025. For the three-month period, the company recorded a net loss of USD 7,100. For the nine-month period ended October 31, 2025, net loss was USD 24,565. The company reported no revenue or gross profit for the three and nine months ended October 31, 2025. As of October 31, 2025, Lvpai Group Ltd. reported cash and cash equivalents of USD 0 and negative operating cash flows of USD 19,465. The company indicated that its working capital requirements remain significant, and it continues to rely on previous financing activities for liquidity and capital resources. Management also noted that recently issued accounting pronouncements are not expected to have a material impact on its financial condition or results of operations. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lvpai Group Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-000624), on February 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### 相關股票

- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [iShares US Medical Devices (IHI.US)](https://longbridge.com/zh-HK/quote/IHI.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md)
- [Enstar (ESGR.US)](https://longbridge.com/zh-HK/quote/ESGR.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [Aptorum (APM.US)](https://longbridge.com/zh-HK/quote/APM.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)

## 相關資訊與研究

- [Clene 2025 net loss narrows as expenses fall](https://longbridge.com/zh-HK/news/278880252.md)
- [Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend](https://longbridge.com/zh-HK/news/279032442.md)
- [Capricor Theraputics Q4 revenue falls to zero, net loss widens](https://longbridge.com/zh-HK/news/278939139.md)
- [Will KETAFREE Become The First FDA-Approved Preservative-Free Ketamine Formulation?](https://longbridge.com/zh-HK/news/279285510.md)
- [Century Therapeutics 2025 net loss narrows beating estimates](https://longbridge.com/zh-HK/news/278880556.md)